...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance
【24h】

Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance

机译:超级pH敏感的多功能聚合物胶束,可用于肿瘤pH(e)特异性TAT暴露和多重耐药

获取原文
获取原文并翻译 | 示例

摘要

As an alternative to cell specific cancer targeting strategies (which are often afflicted with the heterogeneity of cancer cells as with most biological systems), a novel polymeric micelle constitute of two block copolymers of poly(L-lactic acid)-b-poly(ethylene glycol)-b-poly(L-histidine)-TAT (transactivator of transcription) and poly(L-histidine)-b-poly(ethylene glycol) was developed. The micelle formed via the dialysis method was approximately 95 nm in diameter and contained 15 wt.% of doxorubicin (DOX) by weight. The micelle surface hides TAT during circulation, which has the strong capability to translocate the micelle into cells. and exposes TAT at a slightly acidic tumor extracellular pH to facilitate the internalization process. The micelle core was engineered for disintegration in early endosomal pH of tumor cells, quickly releasing DOX. The ionization process of the block copolymers and ionized polymers assisted in disrupting the endosomal membrane. This processes permitted high DOX concentrations in the cytosol and its target site of the nucleus, thus increasing DOX potency in various wild and multidrug resistant (MDR) cell lines (3.8-8.8 times lower IC50 than free DOX, depending on cell line). When tested with the xenografted tumors of human ovarian tumor drug-resistant A2780/AD, human breast tumor drug-sensitive MCF-7, human lung tumor A549 and human epidermoid tumor KB in a nude mice model, all tumors significantly regressed in size by three bolus injections at a dose of DOX 10 mg equivalent/kg body per injection of DOX-loaded micelle at three day interval, while minimum weight loss was observed. This approach may replace the need for cell-specific antibodies or targeting ligands, thereby providing a general strategy for solid tumor targeting. (C) 2008 Elsevier B.V. All rights reserved.
机译:作为细胞特异性癌症靶向策略(通常与大多数生物系统一样常受癌细胞异质性困扰)的替代方法,新型的聚合物胶束由聚(L-乳酸)-b-聚(乙烯)的两种嵌段共聚物组成乙二醇)-b-聚(L-组氨酸)-TAT(转录反式激活剂)和聚(L-组氨酸)-b-聚(乙二醇)被开发出来。通过透析方法形成的胶束的直径约为95nm,并且包含按重量计15重量%的阿霉素(DOX)。胶束表面在循环过程中隐藏了TAT,这具有将胶束转运到细胞中的强大能力。并在微酸性肿瘤细胞外pH下暴露TAT,以促进内在化过程。胶束核心经过改造,可在肿瘤细胞的早期内体pH值中崩解,从而迅速释放DOX。嵌段共聚物和离子化聚合物的电离过程有助于破坏内体膜。该过程允许细胞溶质及其细胞核的靶位点具有较高的DOX浓度,从而提高了各种野生和耐多药(MDR)细胞系的DOX效能(取决于游离细胞系,IC50比游离DOX低3.8-8.8倍)。在裸鼠模型中对人卵巢肿瘤耐药性A2780 / AD,人乳腺癌肿瘤敏感性MCF-7,人肺肿瘤A549和人表皮样肿瘤KB的异种移植肿瘤进行测试时,所有肿瘤的大小均明显缩小了3每三天间隔一次注药,每次注药量为10毫克当量/千克体重,同时观察到最小的体重减轻。这种方法可以代替对细胞特异性抗体或靶向配体的需求,从而为实体瘤靶向提供一般策略。 (C)2008 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号